| Title: |
SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab |
| Authors: |
Martin Heller; Clara Henrici; Judith Büttner; Sebastian Leube; Isabelle Treske; Petra Pospischil; Michael Doll; Ilka Schanz; Agnes Hallier; Eva Herrmann; Michael Schmidt; Christoph Sarrazin |
| Source: |
International Journal of Infectious Diseases, Vol 129, Iss , Pp 260-265 (2023) |
| Publisher Information: |
Elsevier, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Infectious and parasitic diseases |
| Subject Terms: |
COVID-19; Bamlanivimab; Casirivimab; Imdevimab; Antibody therapy; Viral load; Infectious and parasitic diseases; RC109-216 |
| Description: |
Objectives: In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed. Methods: Patients in the intervention groups received bamlanivimab or casirivimab/imdevimab. Patients without treatment served as control. Outcomes were assessed by clinical symptoms and change in log viral load from baseline based on the cycle threshold over a period of 18 days. Results: Median log viral load decline was higher in both intervention groups after 3 and 6 days compared to control. However, at later time points, the decline of the viral load was more distinct in the control group. Mild symptoms of COVID-19 were observed in 6.3% of the intervention groups and in no patient of the control. No patients treated with bamlanivimab, 18.8% treated with casirivimab/imdevimab, and 14.2% in the control group developed moderate symptoms. Severe symptoms were recorded only in the control group (14.2%), including one related death. Conclusion: Treatment with monoclonal SARS-CoV-2 antibodies seems to accelerate decline of virus loads, especially in the first 6 days after administration, compared to control. This may be associated with a reduced likeliness of a severe course of COVID-19. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1201-9712 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S1201971223000127; https://doaj.org/toc/1201-9712 |
| DOI: |
10.1016/j.ijid.2023.01.012 |
| Access URL: |
https://doaj.org/article/b89c38cffdf0416ba36498e3a5265dba |
| Accession Number: |
edsdoj.b89c38cffdf0416ba36498e3a5265dba |
| Database: |
Directory of Open Access Journals |